Evidence Hub

Oleanolic Acid as an Adjunct in Type 2 Diabetes

Günther A, Bednarczyk-Cwynar B, Malinowski M

2026

Abstract

Background: : Type 2 diabetes mellitus is a progressive cardiometabolic disease in which many patients require treatment intensification despite lifestyle intervention and evidence-based pharmacotherapy. Oleanolic acid, a pentacyclic triterpenoid found in olives and other plants, has shown insulin-sensitizing, antioxidant, anti-inflammatory, and hepatometabolic effects in experimental models.

Aim:: This review evaluates oleanolic acid as a potential adjunctive intervention in type 2 diabetes, emphasizing translational evidence, formulation-dependent bioavailability, clinical endpoints, and patient relevance.

Methods:: We performed a narrative translational review of mechanistic, preclinical, pharmacokinetic, clinical, and trial-registry evidence on oleanolic acid, insulin resistance, prediabetes, and type 2 diabetes.

Results:: Preclinical studies support multiple mechanisms by which oleanolic acid may influence glucose homeostasis, including modulation of insulin signaling, hepatic glucose production, oxidative stress, inflammatory pathways, lipid metabolism, and beta-cell vulnerability. Human evidence remains limited but clinically relevant. PREDIABOLE reported reduced progression from prediabetes to type 2 diabetes after long-term intake of oleanolic acid-enriched olive oil. BIO-OLTRAD demonstrated measurable systemic exposure after a 30 mg dose delivered in functional olive oil, with transport through albumin and triglyceride-rich lipoproteins. OLTRAD is testing whether…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free